NGEN
Income statement / Annual
Last year (2024), NervGen Pharma Corp's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, NervGen Pharma Corp's net income was -$16.68 M.
See NervGen Pharma Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$58.23 K
|
$109.40 K
|
$84.92 K
|
$33.70 K
|
$31.12 K
|
$29.47 K
|
$14.47 K
|
$0.00
|
| Gross Profit |
-$58.23 K
|
-$109.40 K
|
-$84.92 K
|
-$33.70 K
|
-$31.12 K
|
-$29.47 K
|
-$14.47 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$10.89 M
|
$6.04 M
|
$12.22 M
|
$5.40 M
|
$4.81 M
|
$4.97 M
|
$571.39 K
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.38 M
|
$7.27 M
|
$4.68 M
|
$4.69 M
|
$3.95 M
|
$2.61 M
|
$408.79 K
|
$9.43 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$17.27 M
|
$13.30 M
|
$16.90 M
|
$10.09 M
|
$8.76 M
|
$7.58 M
|
$980.17 K
|
$9.43 K
|
| Cost And Expenses |
$17.33 M
|
$13.41 M
|
$16.99 M
|
$10.13 M
|
$8.79 M
|
$7.61 M
|
$994.64 K
|
$9.43 K
|
| Interest Income |
$564.69 K
|
$415.03 K
|
$148.57 K
|
$23.26 K
|
$14.80 K
|
$76.21 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$379.62 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$58.23 K
|
$109.40 K
|
$84.92 K
|
$33.70 K
|
$31.12 K
|
$29.47 K
|
$14.47 K
|
$0.00
|
| EBITDA |
-$16.62 M |
-$16.78 M |
-$14.82 M |
-$10.03 M |
-$8.75 M |
-$7.50 M |
-$980.17 K |
-$9.43 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$643.55 K
|
-$3.47 M
|
$1.70 M
|
$66.92 K
|
$7.65 K
|
$76.21 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$16.68 M
|
-$16.89 M
|
-$15.29 M
|
-$10.06 M
|
-$8.78 M
|
-$7.53 M
|
-$994.64 K
|
-$9.43 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$16.68 M
|
-$16.89 M
|
-$15.29 M
|
-$10.06 M
|
-$8.78 M
|
-$7.53 M
|
-$994.64 K
|
-$9.43 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.25 |
-0.28 |
-0.29 |
-0.26 |
-0.27 |
-0.29 |
-0.0365 |
0 |
| EPS Diluted |
-0.25 |
-0.28 |
-0.29 |
-0.26 |
-0.27 |
-0.29 |
-0.0365 |
0 |
| Weighted Average Shares Out |
$67.32 M
|
$59.29 M
|
$52.65 M
|
$39.29 M
|
$32.11 M
|
$25.90 M
|
$27.20 M
|
$27.20 M
|
| Weighted Average Shares Out Diluted |
$67.32 M
|
$59.29 M
|
$52.65 M
|
$39.29 M
|
$32.11 M
|
$25.90 M
|
$27.20 M
|
$27.20 M
|
| Link |
|
|
|
|
|
|
|
|
